vimarsana.com

Netherlands Based Byondis News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Byondis, Medac File for European Approval of SYD985 for HER2-Positive Breast Cancer

Regulators will review data form the TULIP trial, showing the antibody-drug conjugate had a progression-free survival advantage versus physician's choice of treatment.

Medac, Byondis Strike Commercialization Pact for HER2-Targeted Antibody-Drug Conjugate

Byondis is hoping to launch the agent, SYD985, in the UK and EU as a treatment for HER2-positive advanced breast cancer.

BioSpace Movers & Shakers, July 16

BioSpace Movers & Shakers, July 16
biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.